Opitor

Opitor is a clinical-stage biopharmaceutical company based in Stockholm, Sweden, that specializes in the repurposing of established drugs for new therapeutic indications in oncology. The company's lead program, OPI-101, is a proprietary formulation of the anthelmintic drug mebendazole being developed for the treatment of glioblastoma multiforme (GBM). By leveraging the extensive safety and pharmacokinetic data of existing compounds, Opitor aims to significantly reduce the time and cost associated with traditional drug development. The company focuses on hard-to-treat cancers where its repurposed candidates can inhibit microtubule polymerization and induce apoptosis in tumor cells. Opitor's strategy involves identifying high-potential candidates for repositioning to address significant unmet medical needs in the oncology space.